IPL 512602

Drug Profile

IPL 512602

Alternative Names: AVE 0547; IPL 512,602

Latest Information Update: 05 Jun 2007

Price : $50

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Allergic rhinitis; Asthma

Most Recent Events

  • 29 Jan 2007 Inflazyme completes the phase IIb CAPSICS trial for Asthma in the US, Eastern Europe, Russia and Ukraine
  • 17 Nov 2006 Inflazyme has completed enrolment in the CAPSICS trial for Asthma in the US, Eastern Europe, Russia and Ukraine
  • 29 Jun 2005 IPL 512602 is available for partnering (http://www.inflazyme.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top